Increased levels of antibodies to synaptopodin and annexin 1 in patients with primary podocytopathies
Frontiers in Nephrology · 31.10.2024 · 4
DOI: 10.3389/fneph.2024.1471078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nephrology, online erschienen am 31.10.2024. Verfasst von Natalia V Chebotareva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Support Foundation.
Abstract (Originalsprache)
Introduction
Circulating anti-podocyte antibodies have been proposed as potential factors contributing to increased permeability in primary podocytopathies, such as Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS). The aim of the study was to to assess the levels of antibodies targeting synaptopodin and annexin 1 in the blood serum of patients diagnosed with nephrotic syndrome, with the aim of evaluating their potential utility in diagnosing primary podocytopathies and predicting therapeutic response.
Methods
The study included a total of 72 patients diagnosed with nephrotic syndrome, alongside 21 healthy subjects for comparison. Among the patients, 38 were diagnosed with FSGS, 12 with MCD, and 22 with MN. The levels of anti-synaptopodin and anti-annexin-1 antibodies were quantified using Enzyme-Linked Immunosorbent Assay.
Results
The levels of antibodies to annexin 1 and anti-synaptopodin in the blood were found to be higher in patients diagnosed with MCD and FSGS compared to those with MN and healthy individuals. The elevated levels of antibodies to annexin 1 and synaptopodin showed area under the curve values of 0.826 (95% CI 0.732–0.923) and 0.827 (95% CI 0.741–0.879), respectively. However, a model incorporating both antibodies demonstrated higher sensitivity (80.9%) and specificity (81.3%) with an AUC of 0.859 (95% CI 0.760-0.957). Notably, serum levels of annexin 1 and anti-synaptopodin antibodies did not predict the response to prednisolone and/or CNI therapy.
Discussion
Levels of antibodies targeting synaptopodin and annexin 1 were notably elevated in patients diagnosed with MCD and FSGS compared to those with MN and healthy controls. A panel comprising both antibodies demonstrated moderate to high sensitivity and specificity for diagnosis MCD or FSGS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia.
- Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia.
- Department of Prediction of Conservative Treatment Efficiency, Hertsen Moscow Oncology Research Institute, Moscow, Russia.
- Project Center of Advanced Mass, Spectrometry Technologies, Skolkovo Institute of Science and Technology, Moscow, Russia.
Förderung
- Russian Science Support Foundation
Zitieren
APA
Chebotareva, N. V., Charionovskaya, E. A., Biryukova, E. A., Vinogradov, A. A., Alentov, I. I., Sergeeva, N. S., Kononikhin, A. S., Nikolaev, E. N., & Moiseev, S. V. (2024). Increased levels of antibodies to synaptopodin and annexin 1 in patients with primary podocytopathies. Frontiers in Nephrology, 4. https://doi.org/10.3389/fneph.2024.1471078
Vancouver
Chebotareva NV, Charionovskaya EA, Biryukova EA, Vinogradov AA, Alentov II, Sergeeva NS, et al. Increased levels of antibodies to synaptopodin and annexin 1 in patients with primary podocytopathies. Frontiers in Nephrology. 2024;4. doi:10.3389/fneph.2024.1471078
BibTeX
@article{Chebotareva2024,
author = {Chebotareva, Natalia V and Charionovskaya, Evgeniya A and Biryukova, Evgenia A and Vinogradov, Anatoliy A and Alentov, Igor I and Sergeeva, Natalia S and Kononikhin, Alexey S and Nikolaev, Evgeny N and Moiseev, Sergey V},
title = {Increased levels of antibodies to synaptopodin and annexin 1 in patients with primary podocytopathies},
journal = {Frontiers in Nephrology},
year = {2024},
volume = {4},
doi = {10.3389/fneph.2024.1471078}
}
EUVIMED